DOCSLIB.ORG

Alpha-Adrenoceptor Blockade Prevents Exercise-Induced Vasoconstriction of Stenotic Coronary Arteries Barbara K

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Alpha-Adrenoceptor Blockade Prevents Exercise-Induced Vasoconstriction of Stenotic Coronary Arteries Barbara K View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Journal of the American College of Cardiology Vol. 33, No. 6, 1999 © 1999 by the American College of Cardiology ISSN 0735-1097/99/$20.00 Published by Elsevier Science Inc. PII S0735-1097(99)00053-4 Endothelial Function Alpha-Adrenoceptor Blockade Prevents Exercise-Induced Vasoconstriction of Stenotic Coronary Arteries Barbara K. Julius, MD,* Giuseppe Vassalli, MD,* Lazar Mandinov, MD,† Otto M. Hess, MD† Zurich and Bern, Switzerland OBJECTIVES The study aimed to evaluate the role of alpha-adrenergic mechanisms during dynamic exercise in both normal and stenotic coronary arteries. BACKGROUND Paradoxical vasoconstriction of stenotic coronary arteries has been reported during dynamic exercise and may be due to several factors such as alpha-adrenergic drive, a decreased release of nitric oxide, platelet aggregation with release of serotonin, or a passive collapse of the vessel wall. METHODS Twenty-six patients were studied at rest, during two levels of supine bicycle exercise and after 1.6 mg sublingual nitroglycerin. The alpha-blocker phentolamine was given to 16 patients before exercise, five of whom had also taken a beta-adrenergic-blocker the same morning. Ten patients served as controls. The cross-sectional areas of a normal and a stenotic coronary vessel were determined by biplane quantitative coronary arteriography. RESULTS In the normal vessel segments, coronary cross-sectional area did not change after phentol- amine injection, but increased in all patient groups similarly during exercise. Although coronary vasoconstriction existed in stenotic vessel segments in control patients, phentolamine-treated patients showed exercise-induced vasodilation without difference in patients with and without chronic beta-blockade. CONCLUSIONS Exercise-induced vasoconstriction of stenotic coronary arteries is prevented by intracoronary administration of phentolamine. There was no difference in coronary vasomotion between patients receiving phentolamine alone and patients receiving phentolamine in addition to a beta-blocker. This finding suggests that exercise-induced vasoconstriction is mediated not only by endothelial dysfunction but also by alpha-adrenergic mechanisms. (J Am Coll Cardiol 1999;33:1499–505) © 1999 by the American College of Cardiology Coronary vasomotor tone plays an important role in the The exact mechanism that is responsible for the reported pathophysiology of angina pectoris. An increase in vasomo- stenosis vasoconstriction is not clear but may involve several tor tone of stenotic arteries may result in a decrease in factors such as an enhanced sympathetic stimulation during coronary blood flow and, thus, may precipitate myocardial exercise, endothelial dysfunction with reduced nitric oxide ischemia. A reduction in exercise-induced angina pectoris (NO) release or production, increased platelet aggregation and an increase in physical working capacity have been with release of serotonin and thromboxane A2, or a passive reported in patients with stable angina pectoris after intra- collapse of the stenotic vessel segment within the stenosis due coronary administration of phentolamine (1,2) or in- to the increase in flow velocity during exercise (Venturi effect). doramine, a selective alpha1-adrenoceptor antagonist (3). Because changes in coronary vasomotor tone underlie Stenotic coronary arteries have shown paradoxical vasocon- neurogenic mechanisms, particular interest has focused on striction during isometric (4) but also dynamic exercise (5). the link between myocardial ischemia and alpha-adrenergic This exercise-induced narrowing of the stenotic arteries has tone during exercise. Thus, the purpose of the present study been prevented by intracoronary administration of nitro- was to assess the influence of alpha-adrenergic mechanisms glycerin (4) or diltiazem in doses that did not induce on coronary vasomotion in normal and stenotic coronary systemic vascular effects (6). arteries during dynamic exercise. METHODS From the Department of Internal Medicine, Cardiology, *University Hospital, Study population. Twenty-six patients (mean age 54 6 8 Zurich, and †Inselspital, Bern, Switzerland. Manuscript received May 19, 1998; revised manuscript received October 29, 1998, years) with coronary artery disease and stable angina pecto- accepted January 20, 1999. ris were included in the present analysis. Biplane coronary 1500 Julius et al. JACC Vol. 33, No. 6, 1999 Alpha-adrenergic Coronary Vasoconstriction May 1999:1499–505 exercise. Biplane left coronary angiography was performed Abbreviations and Acronyms at the end of the diagnostic coronary angiography. For the ANOVA5 analysis of variance purpose of the present study protocol, the left coronary C 5 controls artery was selected to have a normal and a stenotic vessel 5 CSA cross-sectional area segment for quantitative analysis. The study drug was, NS 5 not significant P 5 patients receiving intracoronary phentolamine therefore, infused over the guiding catheter into the left 5 P(a) patients receiving only phentolamine coronary artery. Eight milliliters of a nonionic contrast 5 R P(a 1 b) patients on chronic beta-blockade receiving material (Jopamiro 370 ) was injected into the left coronary phentolamine artery at a flow rate of 4 ml/s using an electrogram-triggered 5 SD standard deviation power-injector. First, biplane coronary angiography was carried out at rest with the patients’ legs elevated and attached to the bicycle ergometer. Angiography was performed on a Bicor Siemens angiography was performed at rest, during supine bicycle system (Siemens Albis AG, Zurich) using cinefilm at a rate exercise and after sublingual nitroglycerin. Patients who of 25 frames/s. Further biplane coronary angiograms were fulfilled the following baseline criteria were included in the performed after administration of 2 mg intracoronary phen- study: 1) a history of stable, effort-related angina pectoris tolamine (Infusion time: 5 min; 0.4 mg/min). Two levels of and 2) coronary artery stenosis clearly visible on angiography supine bicycle exercise were performed for 2 min in each for quantitative evaluation. The first 10 of the studied patient. Biplane coronary angiography was repeated imme- patients did not receive any premedication prior to exercise diately after each exercise level while the patient was asked and they served as controls (C). The remaining 16 patients to hold his breath. Finally, coronary angiography was obtained before exercise 2 mg intracoronary phentolamine, carried out 5 min following administration of 1.6 mg a nonselective alpha-blocker (P). Although 11 patients of sublingual nitroglycerin. Aortic and pulmonary artery pres- this group did not have any vasoactive substances for at least sures were recorded continuously during exercise and were 24 h before the study (Pa), five patients who were on measured for subsequent analysis immediately before each chronic cardioselective beta-blockade (metoprolol or ateno- angiogram. No adverse event occurred during the study, and lol) had been instructed to take this medication also on the there were no complications with regard to this study morning of the study (Pa 1 b). protocol. Functional classification according to the New York Heart Association was 1.9 6 0.6 in controls and 1.8 6 0.9 Quantitative coronary angiography. Quantitative angio- in the phentolamine-treated patients (not significant [NS]). graphy was carried out with a semiautomatic computer In the phentolamine-treated group, 4/11 patients had one- system (7–9). The system is based on a 35-mm film vessel disease, 4/11 patients had two-vessel disease, and projector (Tagarno 35 CX, Horsens, Denmark), a slow scan 3/11 patients had three-vessel disease. Two patients who CCD-camera for image digitation and a computer work- were pretreated with a beta-adrenergic-blocker and then station (Apollo DN 3000, Wangen, Switzerland) for image received phentolamine during the study protocol were storing and processing. Contour detection was carried out suffering from one-vessel disease, one had a two-vessel with the use of a geometric-densitometric edge detection disease and two had a three-vessel disease. Of the control algorithm (8,10,11). The method for quantitative evaluation patients one-vessel disease was present in 4/10 patients, of coronary angiography has been described in detail else- two-vessel disease was found in 3/10 patients, and three- where (5,7,10,11). vessel disease was present in 3/10 patients. Maximal stenosis Both a normal and a stenotic vessel segment were chosen severity for patients with phentolamine was ,70% in three, for quantitative analysis. In each patient at least one stenotic 70% to 90% in four and .90% in three cases. For patients vessel was selected for analysis on the basis of clear visual- with alpha- and beta-blockade stenosis, severity amounted ization without overlapping vessels. The normal vessel to 70% to 90% in 4 patients and ,70% in 1 patient. One segment was selected from a disease-free vessel when control patient had a ,70% stenosis, seven had 70% to 90% possible, otherwise an uninvolved prestenotic vessel segment stenoses, and 2 had .90% stenoses. Left ventricular ejection was chosen at least four catheter-widths from the center of fraction averaged 61 6 8% in controls and 64 6 6% in the stenosis, which was not used for quantiative evaluation phentolamine-treated patients (NS). (Fig. 1). Cardiac catheterization. The study protocol
Load more

Recommended publications
  • Pharmacology in MS Advanced Practice Management
    Pharmacology in MS Advanced Practice Management Heidi Maloni APRN, BC [email protected] Objectives • Discuss basic principles of pharmacology, pharmacokinetics and pharmacodynamics. • Describe the pharmacotherapeutics of drugs used in MS • Identify the role of advanced practice nurse in MS pharmacological management. Advanced Practice Pharmacology Background • Pharmacology: study of a drug’s effects within a living system • Each drug is identified by 3 names: chemical, generic, trade or marketing name N-4-(hydroxyphenyl) acetamide; acetaminophen; Tylenol sodium hypochlorite; bleach; Clorox 4-(diethylamino)-2-butynl ester hydrochloride; oxybutynin chloride; Ditropan • Drugs are derived from: plants, humans, animals, minerals, and chemical substances • Drugs are classified by clinical indication or body system APN Role Safe drug administration Nurses are professionally, legally, morally, and personally responsible for every dose of medication they prescribe or administer Know the usual dose Know usual route of administration Know significant side effects Know major drug interactions Know major contraindication Use the nursing process Pregnancy Safety • Teratogenicity: ability to produce an abnormality in the fetus (thalidomide) • Mutogenicity: ability to produce a genetic mutation (diethylstilbestrol, methotrexate) Pregnancy Safety Categories • A: studies indicate no risk to the fetus (levothyroxan; low dose vitamins, insulin) • B: studies indicate no risk to animal fetus; information in humans is not available (naproxen;acetaminophen; glatiramer
    [Show full text]
  • Comparison of Different Alpha-Blocker Combinations in Male Hypertensives with Refractory Lower Urinary Tract Symptoms
    대한남성과학회지：제 29 권 제 3 호 2011년 12월 Korean J Androl. Vol. 29, No. 3, December 2011 http://dx.doi.org/10.5534/kja.2011.29.3.242 Comparison of Different Alpha-blocker Combinations in Male Hypertensives with Refractory Lower Urinary Tract Symptoms Keon Cheol Lee1, Jong Gu Kim2, Sung Yong Cho1, Joon Sung Jeon1, In Rae Cho1 Department of Urology, 1Inje University Ilsanpaik Hospital, Goyang, 2Happy Urology Clinic, Ansan, Korea =Abstract= Purpose: We compared the efficacy and safety profiles of dose increase, traditional combination methods, and combining different alpha blockers in hypertensive males with lower urinary tract symptom (LUTS) refractory to an initial dose of 4 mg doxazosin. Materials and Methods: Between 2000 and 2005, 374 male patients with LUTS and hypertension unresponsive to 4 weeks of 4 mg doxazosin were enrolled. The subjects were randomly classified into 3 groups, 8 mg/day of doxazosin (D group), 4 mg of doxazosin plus 0.2 mg/day of tamsulosin (DT group), and 4 mg doxazosin plus 5 mg/day finasteride (DF group). Patients were evaluated based on their International Prostate Symptom Score (IPSS), quality of life (QOL), uroflowmetry and blood pressure (BP) and adverse events (AEs) at the baseline and 3 and 12 months after treatment. Results: The 269 patients (71.9%) were followed for at least 1 year (D group n=84, DT group n=115, and DF group n=70). The clinical parameters before and after initial 4 mg/day doxazosin were not different among the 3 groups. IPSS improvement after 3 months and maximal flow rate (Qmax) improvement after 3 and 12 months were significantly higher in the D and DT groups than the DF group (p＜0.05).
    [Show full text]
  • Airway Receptors
    Postgraduate Medical Journal (1989) 65, 532- 542 Postgrad Med J: first published as 10.1136/pgmj.65.766.532 on 1 August 1989. Downloaded from Mechanisms of Disease Airway receptors Peter J. Barnes Department of Thoracic Medicine, National Heart and Lung Institute, Dovehouse Street, London SW3 6L Y, UK. Introduction Airway smooth muscle tone is influenced by many indirect action which, in part, is due to activation of a hormones, neurotransmitters, drugs and mediators, cholinergic reflex, since the bronchoconstriction may which produce their effects by binding to specific be reduced by a cholinergic antagonist. Other surface receptors on airway smooth muscle cells. mediators may have a bronchoconstrictor effect Bronchoconstriction and bronchodilatation may which, in the case of adenosine, is due to mast cell therefore be viewed in terms of receptor activation or mediator release,2 or in the case of platelet-activating blockade and the contractile state of airway smooth factor due to platelet products.3 muscle is probably the resultant effect of interacting excitatory and inhibitory receptors. Epithelial-derived relaxantfactor It is important to recognize that airway calibre is not only the result of airway smooth muscle tone, but in Recently there has been considerable interest in the asthma it is likely that airway narrowing may also be possibility of a relaxant factor released from airway explained by oedema of the bronchial wall (resulting epithelial cells, which may be analogous to relaxant factor.4 The presence of from microvascular leakage) and to luminal plugging endothelial-derived by copyright. by viscous mucus secretions and extravasated plasma airway epithelium in bovine airways in vitro reduces proteins, which may be produced by a 'soup' of the sensitivity to and maximum contractile effect of mediators released from inflammatory cells, including spasmogens, such as histamine, acetylcholine or mast cells, macrophages and eosinophils.
    [Show full text]
  • Provider- Pain Quick Reference Guide
    A QUICK REFERENCE GUIDE (2019) PBM Academic Detailing Service Posttraumatic Stress Disorder A VA Clinician's Guide to Optimal Treatment of Posttraumatic Stress Disorder (PTSD) VA PBM Academic Detailing Service Real Provider Resources Real Patient Results Your Partner in Enhancing Veteran Health Outcomes VA PBM Academic Detailing Service Email Group [email protected] VA PBM Academic Detailing Service SharePoint Site https://vaww.portal2.va.gov/sites/ad VA PBM Academic Detailing Public Website http://www.pbm.va.gov/PBM/academicdetailingservicehome.asp Table of Contents Abbreviations . 1 PTSD Treatment Decision Aid . 3 VA/DoD 2017 Clinical Practice Guideline: Treatment of PTSD . 4 First-Line Treatment: Trauma-focused Psychotherapies with the Strongest Evidence . 5 First-Line Treatment: Trauma-Focused Psychotherapies with Sufficient Evidence . 6 Comparison of Antidepressants Studied in PTSD . 7 Recommended Antidepressant For PTSD: Dosing . 9 Additional Medications Studied in PTSD: Dosing . 11 Switching Antidepressants . 12 Antidepressants and Sexual Dysfunction . 14 i TOC (continued) Sexual Dysfunction Treatment Strategies . 16 Antidepressants and Hyponatremia . 17 Additional Pharmacotherapy Options for Veterans Refractory to Standard Treatments . 19 Discussing Benzodiazepine Withdrawal . 21 Prazosin Tips . 25 Prazosin Precautions . 26 Managing PTSD Nightmares in Veterans with LUTS Associated with BPH . 27 Other Medications Studied in PTSD-Related Nightmares . 29 References . 30 ii Abbreviations Anti-Ach = anticholinergic
    [Show full text]
  • Oral Phentolamine: an Alpha-1, Alpha-2 Adrenergic Antagonist for the Treatment of Erectile Dysfunction
    International Journal of Impotence Research (2000) 12, Suppl 1, S75±S80 ß 2000 Macmillan Publishers Ltd All rights reserved 0955-9930/00 $15.00 www.nature.com/ijir Oral phentolamine: an alpha-1, alpha-2 adrenergic antagonist for the treatment of erectile dysfunction I Goldstein1 1Department of Urology, Boston University School of Medicine, Boston, MA, USA Phentolamine mesylate is an alpha-1 and alpha-2 selective adrenergic receptor antagonist which has undergone clinical trials for erectile dysfunction treatment. Biochemical and physiological studies in human erectile tissue have revealed a high af®nity of phentolamine for alpha-1 and alpha-2 adrenergic receptors. Based on pharmacokinetic studies, it is suggested that 30±40 min following oral ingestion of 40 or 80 mg of phentolamine (Vasomax), the mean plasma phentolamine concentrations are suf®cient to occupy the alpha-1 and -2 adrenergic receptors in erectile tissue and thereby result in inhibition of adrenergic-mediated physiologic activity. In large multi-center, placebo-controlled pivotal phase III clinical trials, the mean change in the erectile function domain of the International Index of Erectile Function scores (Questions 1±5 and 15) from screening to the end of treatment was signi®cantly higher following use of active drug (40 mg and 80 mg) compared to placebo. Three to four times as many patients receiving phentolamine reported being satis®ed or very satis®ed compared with those receiving placebo. At doses of 40 mg and 80 mg respectively, 55% and 59% of men were able to achieve vaginal penetration with 51% and 53% achieving penetration on 75% of attempts.
    [Show full text]
  • Therapeutic Drug Class
    BUREAU FOR MEDICAL SERVICES WEST VIRGINIA MEDICAID EFFECTIVE PREFERRED DRUG LIST WITH PRIOR AUTHORIZATION CRITERIA 10/1/12 This is not an all-inclusive list of available covered drugs and includes only managed categories. Refer to cover page for complete list of rules governing this PDL. Version 2012.7b Prior authorization for a non-preferred agent in any category will be given only if there has been a trial of the preferred brand/generic equivalent or preferred formulation of the active ingredient, at a therapeutic dose, that resulted in a partial response with a documented intolerance. Prior authorization of a non-preferred isomer, pro-drug, or metabolite will be considered with a trial of a preferred parent drug of the same chemical entity, at a therapeutic dose, that resulted in a partial response with documented intolerance or a previous trial and therapy failure, at a therapeutic dose, with a preferred drug of a different chemical entity indicated to treat the submitted diagnosis. (The required trial may be overridden when documented evidence is provided that the use of these preferred agent(s) would be medically contraindicated.) Unless otherwise specified, the listing of a particular brand or generic name includes all legend forms of that drug. OTC drugs are not covered unless specified. PA criteria for non-preferred agents apply in addition to general Drug Utilization Review policy that is in effect for the entire pharmacy program, including, but not limited to, appropriate dosing, duplication of therapy, etc. The use of pharmaceutical samples will not be considered when evaluating the members’ medical condition or prior prescription history for drugs that require prior authorization.
    [Show full text]
  • (ADAP) Formulary MAY 2021
    Florida AIDS Drug Assistance Program (ADAP) Formulary MAY 2021 *Indicates controlled substance. Unless otherwise noted, all brands, strengths and dosage forms may be ordered pending wholesaler availability. Brand Name (listed for Generic Name Therapeutic Classification Pharmacologic Classification Antiretroviral drugs only) abacavir (ABC) Ziagen Antiretroviral NRTI abacavir/lamivudine (ABC/3TC) Epzicom Antiretroviral NRTI combo abacavir/lamivudine/zidovudine (ABC/3TC/AZT) Trizivir Antiretroviral NRTI combo atazanavir (ATV) Reyataz Antiretroviral PI atazanavir/cobicistat (ATV/COBI) Evotaz Antiretroviral PI/PK Enhancer bictegravir/emtricitabine/tenofovir alafenamide Biktarvy Antiretroviral INSTI/NRTI combo (BIC/FTC/TAF) cabotegravir (CAB) Vocabria Antiretroviral INSTI cabotegravir/rilpivirine (CAB/RPV) Cabenuva Antiretroviral INSTI/NNRTI combo cobicistat (COBI) Tybost Antiretroviral PK Enhancer darunavir (DRV) Prezista Antiretroviral PI darunavir/cobicistat (DRV/COBI) Prezcobix Antiretroviral PI/PK Enhancer darunavir/cobicistat/emtricitabine/tenofovir Symtuza Antiretroviral PI/NRTI combo alafenamide (DRV/COBI/FTC/TAF) dolutegravir (DTG) Tivicay Antiretroviral INSTI dolutegravir / lamivudine (DTG/3TC) Dovato Antiretroviral INSTI/NRTI combo dolutegravir/abacavir/lamivudine (DTG/ABC/3TC) Triumeq Antiretroviral INSTI/NRTI combo dolutegravir/rilpivirine (DTG/RPV) Juluca Antiretroviral INSTI/NNRTI combo doravirine (DOR) Pifeltro Antiretroviral NNRTI doravirine/lamivudine/tenofovir disoproxil fumarate Delstrigo Antiretroviral NNRTI/NRTI combo
    [Show full text]
  • Alpha-Adrenoceptor Antagonists (Alpha-Blockers)
    DRUG CLASSES ALPHA-ADRENOCEPTOR ANTAGONISTS (ALPHA-BLOCKERS) Alpha-blockers are usually used as add-on drugs in difficult to treat hypertension or where other drugs are poorly tolerated. Examples Doxazosin Indoramin Prazosin Terazosin Mechanism of action Commonly used alpha-blockers act selectively at post-ganglionic alpha1-receptors. Selective blockade of peripheral alpha1-receptors leads to vasodilatation and hence reduction in blood pressure. Pharmacokinetics Alpha-blockers are well absorbed after oral administration and undergo extensive hepatic metabolism. The main difference between agents is in elimination half-life: short with indoramin and prazosin and much longer with doxazosin and terazosin. Adverse effects First-dose postural hypotension associated with reflex cardioacceleration and palpitation. Much less common with doxazosin, especially in SR formulation. Vaso-vagal syncope after first dose if unable to mount a rapid heart rate response to hypotension. Caution particularly with terazosin. Headache Oedema Stress incontinence in women Drowsiness with Indoramin 1 Practical issues All alpha-blockers reduce blood pressure. However, doxazosin or terazosin are the preferred options because longer duration of action allows once daily administration. In sustained release formulation, the onset of action of doxazosin is gradual making first- dose hypotension less common. To avoid collapse due to hypotension, it is recomeneded to start terazosin with a low dose given at bedtime. Alpha-blockers are usually used with other agents in the treatment resistant hypertension. In addition to a role in hypertension, alpha-blockers are used to treat benign prostatic hypertrophy. Prazosin is also licensed for the treatment of Raynaud’s syndrome. Alpha- blockers can also be a useful choice in subjects suspected of having phaeochromocytoma.
    [Show full text]
  • A Guide to the Administration of Medicines in the Perioperative
    ......„„.....NHS Grampian Guideline For The Administration Of Medicines In The Pen-Operative Period Co-ordinators: Consultation Group: Approver: Pre-Operative Assessment See Consultation list Medicine Guidelines and Pharmacist Policies Group Signature: Signature: ...i 0 0 a Identifier: Review Date: Date Approved: NHSG/Guid/Peri0p/ May 2022 May 2019 MGPG1026 Uncontrolled when printed Version 3 Executive Sign-Off This document has been endorsed by the Director of Pharmacy and Medicines Management Signature: Title: Guideline for the Administration of Medicines in the Peri- Operative Period Unique Identifier: NHSG/Guid/PeriOp/MGPG1026 Replaces: NHSG/Guid/PeriOp/MGPG697, Version 2 Across NHS Organisation Directorate Clinical Service Sub Boards Wide Department Area This controlled document shall not be copied in part or whole without the express permission of the author or the author’s representative. Lead Author/Co-ordinator: Pre-Operative Assessment Pharmacist Subject (as per document Clinical Guidance registration categories): Key word(s): Peri-operative medication guidance, gastro intestinal system, cardiovascular system, respiratory, central nervous, infections, endocrine, obstetrics, gynaecology, urinary tract, malignant, nutrition, blood, musculoskeletal, joint, corticosteroid treatment, alternative routes, antiepileptic Process Document: Policy, Guideline Protocol, Procedure or Guideline Document application: NHS Grampian Purpose/description: This policy is designed to be used by pharmacy, nursing and medical staff at pre-assessment
    [Show full text]
  • Supplemental Table 2 Revised
    Supplemental Table 2: Additional data validated by the expert panel for inclusion in PIM-Check PIM-Check additional data: Potentially Inappropriate Medications for Patients in Internal Medicine checklist This supplemental table includes PIM-check statements’ additional data. It includes statements’ rational and references and when appropriate recommendations, remarks, and useful links. This tool was validated using a 2-round Delphi method including 40 international experts from Belgium, France, Quebec and Switzerland. Their median level of agreement and useful rating during the second round are indicated for each statement. This is not a replacement for a clinical and biological evaluation by a clinician. The proposals are only applicable in the event there is no patient-specific contraindication. Some drugs listed may not be available in each country. A glossary of all abbreviations used in this tool is available at the end of the table. The *, **, *** symbols refer to information contained in table 3. CARDIOLOGY HEART FAILURE Rational Reduced risk of hospitalisation for heart failure and reduced risk of premature death. Recommendations Suggested dosing regimens: Titration up to effective doses or up to the maximum tolerated dose, while monitoring renal function. Maximum suggested dosing regimens: ACEI: captopril 50 mg TID, enalapril 10–20 mg BID, fosinopril 40 mg QD, lisinopril 20–40 mg QD, perindopril 8–16 mg QD, quinapril 20 mg BID, ramipril 5 mg BID, trandolapril 4 1 mg QD UP ARB: candesartan 32 mg QD, valsartan 160 mg BID, losartan
    [Show full text]
  • Comparison of Alpha Blockers in Treatment of Premature Ejaculation: a Pilot Clinical Trial
    Iranian Red Crescent Medical Journal. 2013 October; 15(10): e13805. DOI: 10.5812.ircmj.13805 Research Article Published Online 2013 October 05. Comparison of Alpha Blockers in Treatment of Premature Ejaculation: A Pilot Clinical Trial 1, * 2 3 1 1 Yigit Akin , Hakan Gulmez , Mutlu Ates , Aliseydi Bozkurt , Baris Nuhoglu 1 Harran University School of Medicine, Department of Urology, Sanliurfa, Turkey 2 Department of Family Medicine, Baskent University School of Medicine, Ankara, Turkey 3 Department of Urology, Afyon Kocatepe University School of Medicine, Afyonkarahisar, Turkey *Corresponding Author : Yigit Akin, Harran University School of Medicine, Department of Urology, 63100, Sanliurfa, Turkey. Tel: +90-5065334999, Fax: +90-4462161819, E-mail: [email protected] Received: ; Revised: ; Accepted: July 25, 2013 August 23, 2013 September 05, 2013 Background: Premature ejaculation (PE) is the most common sexual disorder in men and studies reported prevalence up to 30% (1, 2). PE is not a life-threatening medical condition but it influences the quality of life (QoL). Objectives: The aim of this study was to compare the efficiency, and safety of alpha blocker drugs in the treatment of patients with premature ejaculation (PE). Additionally we investigated the quality of life (QoL) in patients with PE who were treated with alpha blocker drugs. Materials and Methods: This study was a pilot clinical trial. Prospectively documented 108 patients with PE were treated and were followed-up in urology outpatient clinic. All patients were divided into 5 groups according to used alpha blocker agents which were determined by simple randomization. Silodosin 4mg (Group 1, n = 21), tamsulosin hydrochloride 0.4mg (Group 2, n = 23), alfuzosin 10mg (Group 3, n = 22), terazosin 5mg (Group 4, n = 21), doksazosin mesylate 4mg (Group5, n = 21), were used for treatment.
    [Show full text]
  • Faa-Meds.Pdf
    FAA Accepted Medications. FAA FAA Allow Trade Name Drug Classificationti Treatment For Allowed Based On ed Abilify NOT atypical antipsychotic psychosis aripiprazole ALLOWED Accolate antiasthmatic asthma detailed status zafirlukast report from t treating physician Accupril antihypertensive agent high blood pressure hypertension quinapril hypertension evaluation blood pressure Accuretic fixed combination ACE- high blood pressure hypertension ' quinapril inhibitor/diuretic hypertension evaluation HCTZ blood pressure Accutane acne treatment night flying isotretonoin prohibited while le using Aceon ACE inhibitor high blood pressure hypertension ' perindopril erbumine hypertension evaluation t blood pressure Acetaminophen analgesic general pain relief no adverse side numerous label effects brands of OTC products Aciphex gastric acid secreting gastroesophageal reflux status report and rabeprazole inhibitor no adverse side effects Actemra recombinant humanized rheumatoid arthritis NOT Tocilizumab antihuman interleukin 6 ALLOWED receptor Actifed antihistamine allergies 12 hour wait actifed allergic rhinitis before flying common cold Actigall bile acid reduction agent gall stones status report and ursidiol no adverse side effects liver function studies Actonel bone resorption inhibitor osteoporosis status report and risedronate sodium no adverse side effects Actoplus insulin sensitizing agent Diabetes, Type 2 diabetes pioglitazone evaluation metformin Actos oral diabetes agent Diabetes, Type 2 diabetes pioglitazone evaluation Adalat calcium channel
    [Show full text]